| Apr 14 2015 |
A Call to Comment for Telemedicine Stakeholders: The Cadillac Tax |
Epstein Becker & Green, P.C. |
| Apr 14 2015 |
European Court to Clarify Responsibilities and Liability for Medical Devices |
Covington & Burling LLP |
| Apr 14 2015 |
U.S. Department of Transportation Publishes Rule Permitting Use of Electronic Drug Testing Custody and Control Form |
Jackson Lewis P.C. |
| Apr 13 2015 |
Supreme Court Rules That Providers and Suppliers Cannot Challenge Medicaid Reimbursement Rates in Federal Court |
Epstein Becker & Green, P.C. |
| Apr 13 2015 |
Chicago’s Technology Community Includes a Growing Automotive Technology and Research Sector |
Foley & Lardner LLP |
| Apr 10 2015 |
Farmers Markets, Roadside Stands, and CSA Programs Evade the Long Arm of the Law |
Morgan, Lewis & Bockius LLP |
| Apr 9 2015 |
CMS Takes Initial Steps to Address Medicare & Medicaid Coverage for Biosimilars |
Mintz |
| Apr 9 2015 |
Apotex Has Standing Despite Benicar Patent Disclaimer |
Foley & Lardner LLP |
| Apr 9 2015 |
Food Labeling, Food Safety and Nutrition Update |
Mintz |
| Apr 9 2015 |
Massachusetts Announces Significant Changes to the Medical Marijuana Dispensary Program |
Mintz |
| Apr 8 2015 |
European Union Policy Update—April re: Digital Single Market Policy, Finance, Life Sciences and More |
Covington & Burling LLP |
| Apr 8 2015 |
The Newborn Screening Saves Lives Reauthorization Act: Implications for Human Subjects Research |
McDermott Will & Emery |
| Apr 7 2015 |
CMS Releases New Reimbursement Guidance for Biosimilars |
Covington & Burling LLP |
| Apr 7 2015 |
False Advertising Claim Washed Away for Lack of Standing |
Proskauer Rose LLP |
| Apr 7 2015 |
Waiting On Sequenom: Pharma Patents |
Foley & Lardner LLP |
| Apr 6 2015 |
Pay for Delay – Big Pharma’s Dirty Secret |
Mahany Law |
| Apr 3 2015 |
CMS Offers a New Accountable Care Organization Model |
Greenberg Traurig, LLP |
| Apr 2 2015 |
Moving to the Cloud: Some Key Considerations for Healthcare Entities |
Covington & Burling LLP |
| Apr 2 2015 |
Roxane Labs and Par Pharm v. Jazz Pharm: Denying Institution CBM2014-00161, 175 |
Faegre Drinker |
| Mar 31 2015 |
German Exemptions from Mandatory Rebates for Pharma Companies Are in Line with EU State Aid Rules |
Covington & Burling LLP |
| Mar 31 2015 |
No Collateral Challenge Of Patent Application Revival |
Foley & Lardner LLP |
| Mar 30 2015 |
FDA Issues Final Guidance on Reprocessing Medical Devices |
Barnes & Thornburg LLP |
| Mar 30 2015 |
Real Parties in Interest Really Matter: GEA Process Engineering v. Steuben Foods |
McDermott Will & Emery |
| Mar 30 2015 |
Perspectives on the President’s Precision Medicine Initiative |
Foley & Lardner LLP |
| Mar 28 2015 |
Threshold Issues: IPR Not Derailed by Unidentified D/B/A Name or Prior ANDA Certification |
McDermott Will & Emery |
| Mar 28 2015 |
TMI: When Does Fitness Data Become Too Much of a Good Thing? |
Greenberg Traurig, LLP |
| Mar 28 2015 |
PhRMA's Objections to HSR Rule on Exclusive Licenses Face Skeptical Appellate Judges |
ArentFox Schiff LLP |
| Mar 27 2015 |
Strike Two – FDA Rejects Amgen’s Certification Petition for Biosimilar Applicants |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Mar 27 2015 |
Fourth Circuit Sustains Securities Fraud Claim Against Drug Manufacturer |
Katten |
| Mar 26 2015 |
European Food Safety Authority (EFSA) Grants Public Access to Data through Scientific “Data Warehouse” |
Covington & Burling LLP |
| Mar 26 2015 |
FDA Issues Draft Guidance on Use of Electronic Informed Consent in Clinical Trials |
McDermott Will & Emery |
| Mar 26 2015 |
Patent Term Adjustment In The Post-RCE Period -- Request for Continued Examination |
Foley & Lardner LLP |
| Mar 25 2015 |
Failure to Warn About Dangers of Off-Label Use of Medical Device Preempted Under Federal Law |
Varnum LLP |
| Mar 25 2015 |
Teva Pharmaceuticals: Is It Time to Rethink How You Will Argue Claim Construction? |
Dickinson Wright PLLC |
| Mar 25 2015 |
Increased FTC Enforcement as FDA Deregulates Low-Rish Health IT Devices |
Morgan, Lewis & Bockius LLP |
